Targeting apoptotic pathways and the Bcl-2 ortholog in Leishmania may provide effective anti-leishmanial therapies, as shown by the successful use of miltefosine, an anticancer drug, known to induce apoptosis-like cell death in Leishmania sp., in treating leishmaniasis [18]. This evidence concerns the gene BCL2 and leishmaniasis.